Asthma

Truveta delivers largest and most complete mother and child EHR dataset to advance healthcare

Retrieved on: 
Thursday, April 25, 2024
Mortality, Pregnancy, Dermatitis, HIPAA, Bias, Safety, Woman, Risk, Hospital, Certification, Policy, Health, EHR, Health care, MD, Research, ISO, Vaccine, PHI, Human, Comparable, Data, Patient, Privacy, Category, Physician, Gestational age, Mother, Child, Death, Asthma, SDOH, Birth control

Healthcare research has long been challenged with understanding maternal and pediatric health outcomes, often hindered by fragmented data sources and privacy concerns.

Key Points: 
  • Healthcare research has long been challenged with understanding maternal and pediatric health outcomes, often hindered by fragmented data sources and privacy concerns.
  • Now available in Truveta Data, Truveta offers more than one million mother-child pairs, the largest mother-child EHR dataset available today.
  • Truveta delivers regulatory-grade EHR data, including clinician notes and images, linked with claims, social drivers of health (SDOH), and mortality data, providing in-depth insights into patient care.
  • With access to over five years of longitudinal patient data, Truveta offers unparalleled depth and breadth for healthcare research.

Sharecare awarded three-year NCQA Accreditation for Case Management

Retrieved on: 
Wednesday, April 24, 2024
Health Promotion International, Case management, NCQA, Coronary artery disease, Sharecare, Health, Population health, Quality, Diabetes, Quality assurance, Environment, Accreditation, Patient, National Committee, Patient satisfaction, Asthma, Organization, Heart failure, Chronic obstructive pulmonary disease, Nursing

ATLANTA, April 24, 2024 (GLOBE NEWSWIRE) -- Sharecare (Nasdaq: SHCR ), the digital health company that helps people manage all their health in one place, today announced it has received a three-year Case Management Accreditation by the National Committee for Quality Assurance (NCQA) for the complex case management capabilities available through its proprietary advocacy solution.

Key Points: 
  • ATLANTA, April 24, 2024 (GLOBE NEWSWIRE) -- Sharecare (Nasdaq: SHCR ), the digital health company that helps people manage all their health in one place, today announced it has received a three-year Case Management Accreditation by the National Committee for Quality Assurance (NCQA) for the complex case management capabilities available through its proprietary advocacy solution.
  • “Further, combined with our existing three-year accreditations from NCQA for our population health and lifestyle and disease management programs, earning three-year accreditation for our approach to complex case management underscores Sharecare’s ability to build and deploy best-in-class solutions that make healthcare more personalized, accessible, and affordable for everyone.”
    NCQA Accreditation standards are developed with input from researchers in the field, the Case Management Expert Panel and standing committees, employers, both purchasers and operators of Case Management programs, state and federal regulators, and other experts.
  • “Case Management Accreditation moves us closer to measuring quality across population health management initiatives,” said Margaret E. O’Kane, President, NCQA.
  • Sharecare’s NCQA Case Management Accreditation is in addition to the three-year NCQA Population Health Program Accreditation it received in December 2021 for its platform, including programs for coronary artery disease, heart failure, asthma, diabetes, and chronic obstructive pulmonary disease; as well as the three-year NCQA Wellness and Health Promotion Accreditation awarded in August 2022 for Sharecare’s lifestyle and disease management interventions, which include the digital health company’s coaching programs and RealAge health risk assessment.

Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

Retrieved on: 
Tuesday, April 23, 2024
FDA, DSM-IV codes, Prurigo nodularis, Fast track (FDA), Safety, Risk, ITP, Food, Thrombocytopenia, Orphan, Research and development, Development, Patient, Fatigue, Intracranial hemorrhage, LUNA, Asthma, Sanofi, Hematology, BTK, IgG4-related disease

Positive results from the LUNA 3 phase 3 study demonstrated that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients with persistent or chronic immune thrombocytopenia (ITP).

Key Points: 
  • Positive results from the LUNA 3 phase 3 study demonstrated that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients with persistent or chronic immune thrombocytopenia (ITP).
  • The safety profile of rilzabrutinib was consistent with that reported in previous studies.
  • LUNA 3 study met its primary endpoint demonstrating a significantly higher proportion of patients receiving rilzabrutinib achieved the primary endpoint of durable platelet response versus placebo.
  • This clinically and statistically significant result was achieved in a population of patients with primary ITP that had been refractory to prior therapy.

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, April 16, 2024
SCI, FDA, Congress, American Academy, Investment, RAD, NDA, Insurance, Partnership, Research, Week, Patient, AAD, Atopic dermatitis, Arena Pharmaceuticals, Inflammation, Accounting, Annual general meeting, Asthma, Inflammatory Bowel Diseases, Type, Connect, UC, Pharmaceutical industry

Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4Rα, for the treatment of Th2 inflammatory diseases .

Key Points: 
  • Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4Rα, for the treatment of Th2 inflammatory diseases .
  • Four posters at the 2023 World Congress of Dermatology in July 2023 on data from the initial 16-week treatment period with rademikibart of the pivotal trial in China in patients with moderate-to-severe AD.
  • Connect expects to receive an update from Simcere as early as Q2 2024 on these next steps.
  • Cash, cash equivalents and short-term investments were $118.7 million as of December 31, 2023, compared with $161.9 million on December 31, 2022.

Incannex Healthcare Inc. Quarterly Update, Q1 2024

Retrieved on: 
Tuesday, April 16, 2024
FDA, Psilocybin, Pregabalin, Risk, Obstruction, Phase II, IND, NCT, GAD, Serotonin, Biomarker, Sleep, Deficit spending, Inflammation, Benzodiazepine, Pharmacokinetics, Food, HCQ, IRB, Psychotherapy, Diazepam, Quality of life, OSA, Food and Drug Administration, Pain, Patient, Somnolence, Institutional review board, Safety, Tissue, Bronchitis, PRO, Research, Monash University, Joint, Fatigue, EMA, Dronabinol, PAP, Clinical trial, Asthma, AHI, Accident, COPD, Acetazolamide, NDA, Rheumatoid arthritis, Colitis, Joint stiffness, Obstructive sleep apnea, CBD, Disease, Inflammatory bowel disease, Sleep apnea, Hydroxychloroquine, Cannabidiol, Pharmaceutical industry

MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Inc. (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is pleased to provide quarterly activities update and for the quarter ended 31 March 2024.

Key Points: 
  • MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Inc. (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is pleased to provide quarterly activities update and for the quarter ended 31 March 2024.
  • Incannex is undertaking various U.S. Food and Drug Administration (‘FDA’) research and development (‘R&D’) programs for cannabinoid pharmaceutical products and psychedelic medicine therapies.
  • During the quarter, Incannex released top line results from the PsiGAD1 clinical trial conducted at Monash University, based in Melbourne, Australia.
  • This announcement has been approved for release to NASDAQ by the Incannex Board of Directors.

Chiesi USA Appoints Richard Smith as Vice President and Business Unit Leader, U.S. AIR

Retrieved on: 
Monday, April 15, 2024
AIR, U.S. AIR, Chronic obstructive pulmonary disease, Health, Leo Pharma, History, Smith, Patient, Asthma, Organization, COPD

Chiesi USA remains steadfast in its preparations for the full-scale U.S. launch of its AIR franchise as part of the company’s commitment to improving respiratory care and health in communities

Key Points: 
  • Chiesi USA remains steadfast in its preparations for the full-scale U.S. launch of its AIR franchise as part of the company’s commitment to improving respiratory care and health in communities
    CARY, N.C., April 15, 2024 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced it has appointed Richard Smith as vice president and business unit leader of U.S. AIR.
  • Smith will report to Jon Zwinski, CEO and general manager of Chiesi USA.
  • “Richard’s inspirational leadership and track record of enabling actionable programs with multistakeholder engagement reflect Chiesi USA’s mission and values.
  • Before joining Chiesi USA, Smith was vice president and head of the U.S. commercial organization at LEO Pharma, Inc.

Stallergenes Greer Publishes in the Lancet Regional Health-Europe Landmark EfficAPSI Real-world Study Confirming Significant Benefit of Its Liquid Sublingual AIT on the Onset and Progression of Allergic Asthma

Retrieved on: 
Thursday, May 2, 2024
Science, Other Science, Research, Pharmaceutical, General Health, Health, Hospitals, Other Health, Public, Society, Risk, GINA, MD, Doctor of Philosophy, Global Initiative for Asthma, Allergen, AIT, Patient, Allergic rhinitis, Pulmonology, Asthma, Quality of life, Pharmaceutical industry

The primary objective of the study was the evaluation of the real-world impact of Stallergenes Greer SLIT-liquid on the prevention of asthma onset or worsening in patients with allergic rhinitis.

Key Points: 
  • The primary objective of the study was the evaluation of the real-world impact of Stallergenes Greer SLIT-liquid on the prevention of asthma onset or worsening in patients with allergic rhinitis.
  • “Exploring the impact of allergen immunotherapy on asthma onset and progression is crucial, and we're committed to filling those gaps.
  • Through this real-world EfficAPSI study, Stallergenes Greer is honoured to contribute valuable scientific evidence and insights to allergy treatment.
  • By demonstrating the benefit on the onset and worsening of asthma, Stallergenes Greer SLIT-liquid treatments confirm their impact in terms of public health.

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio

Retrieved on: 
Wednesday, May 1, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Mortality, FDA, Risk, ICS, Death, Weight loss, Growth, Gastrointestinal tract, Rash, TSLP, Formoterol, Biopharmaceutical, AstraZeneca, LABA, Inflammation, Salbutamol, Skin, Tezepelumab, Approval, EGPA, AMG, Allergy, Polyp (medicine), Bronchitis, Chronic obstructive pulmonary disease, Patient, Eosinophilic, Sinusitis, Rheumatology, Heart, Atmosphere, Fatigue, Immunology, Budesonide, Lung, Chronic pain, Asthma, COPD, Gastroenterology, Emphysema, Disease, Science, Conditional sentence, Dermatology, Pharmaceutical industry

In addition, we are also collaborating with AstraZeneca on AMG104/AZD8630, an inhaled anti-TSLP compound currently in development for asthma.

Key Points: 
  • In addition, we are also collaborating with AstraZeneca on AMG104/AZD8630, an inhaled anti-TSLP compound currently in development for asthma.
  • Respiratory & Immunology, part of BioPharmaceuticals, is one of AstraZeneca’s main disease areas and is a key growth driver for the Company.
  • With common pathways and underlying disease drivers across respiratory and immunology, AstraZeneca is following the science from chronic lung diseases to immunology-driven disease areas.
  • AstraZeneca’s ambition in Respiratory & Immunology is to achieve disease modification and durable remission for millions of patients worldwide.

Renovion Announces Positive Top-Line Results from Phase 2 CLIMB Study of ARINA-1 (RVN-301) in Patients with Non-Cystic Fibrosis Bronchiectasis

Retrieved on: 
Tuesday, April 30, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Hemoptysis, MCID, Inflammation, Safety, Mucus, QOL, Professor, Bronchiectasis, MD, Doctor of Philosophy, Conference, Mycobacterium, Sputum, Periodic breathing, Urinary tract infection, CAAT, Disease, Chronic cough, Patient, Principal, Aes, Diagnosis, Inc., ITT, American Thoracic Society, Quality of life, Asthma, Bronchitis, National Jewish Health, Division, Infection, COPD, Pharmaceutical industry

The CLIMB study was a randomized double-blind placebo-controlled study to assess the safety and efficacy of ARINA-1 in NCFBE.

Key Points: 
  • The CLIMB study was a randomized double-blind placebo-controlled study to assess the safety and efficacy of ARINA-1 in NCFBE.
  • Participants were randomized (7:3, treatment:placebo), and 40 participants completed the study, with 29 completing in the ARINA-1 arm and 11 in the placebo (0.9% saline) arm.
  • Topline results from the intention-to-treat (ITT) population demonstrate that ARINA-1 is safe and improves quality of life (QOL) in individuals with NCFBE who experience mucus symptoms.
  • Renovion will discuss study results at the American Thoracic Society Meeting (May 17-22) and present findings at the World Bronchiectasis Conference (July 4-6) in Dundee, Scotland.

NuvoAir Medical Partners with Privia Medical Group — Georgia to Help Transform Cardiopulmonary Care with Virtual-First Care Model

Retrieved on: 
Tuesday, April 30, 2024
Nursing, Health, Practice Management, Health Technology, Other Health, General Health, Cardiology, PMG, Accountable care organization, Heart, Communication, Partnership, Asthma, Patient, Physician, ACO, CHF, Multimedia, COPD

This collaboration marks a significant step forward in enhancing access to high-quality cardiopulmonary care for patients throughout the state of Georgia.

Key Points: 
  • This collaboration marks a significant step forward in enhancing access to high-quality cardiopulmonary care for patients throughout the state of Georgia.
  • Privia operates the state’s highest performing Accountable Care Organization (ACO), with more than 380 providers caring for over 515,000 patients.
  • "We are thrilled to have NuvoAir Medical partner with PMG — Georgia to enhance our capabilities in delivering comprehensive, cardiopulmonary care to our patients," said PMG — Georgia’s Chief Medical Officer, Dr. Zia Khan.
  • The partnership between NuvoAir Medical and PMG represents a significant milestone in advancing the future of healthcare delivery and value-based care by combining clinical expertise with cutting-edge technology to help transform cardiopulmonary care for patients throughout the state.